As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
18 Analysts have issued a TransMedics Group, Inc. forecast:
18 Analysts have issued a TransMedics Group, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 531 531 |
48%
48%
|
|
| Gross Profit | 318 318 |
46%
46%
|
|
| EBITDA | 77 77 |
12,703%
12,703%
|
|
| EBIT (Operating Income) EBIT | 77 77 |
9,577%
9,577%
|
|
| Net Profit | 72 72 |
2,289%
2,289%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
| Head office | United States |
| CEO | Waleed Hassanein |
| Employees | 728 |
| Founded | 1998 |
| Website | www.transmedics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


